These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. De Jesus Moreno Moreno M Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119 [TBL] [Abstract][Full Text] [Related]
3. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967 [TBL] [Abstract][Full Text] [Related]
4. Donepezil for dementia due to Alzheimer's disease. Birks JS; Harvey RJ Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184 [TBL] [Abstract][Full Text] [Related]
12. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group. Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427 [TBL] [Abstract][Full Text] [Related]
14. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ; N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease. Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial. Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192 [TBL] [Abstract][Full Text] [Related]
17. Galantamine for Alzheimer's disease and mild cognitive impairment. Loy C; Schneider L Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436 [TBL] [Abstract][Full Text] [Related]
19. Lecanemab in Early Alzheimer's Disease. van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413 [TBL] [Abstract][Full Text] [Related]
20. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]